Do you want to read an article? Please log in or register.
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
Type 2 DiabetesGlycemic Control
COMMENTED
Related content
COMMENTED
Type 2 Diabetes
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.1016/S2213-8587(20)30038-3.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis
JAMA.
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF
doi: 10.1001/jama.2016.9400.
Type 2 Diabetes
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
Diabet Med.
Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ
doi: 10.1111/dme.
COMMENTED
Type 2 Diabetes
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Ann Intern Med.
Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E
doi: 10.7326/M20-0864.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials
Diabetes Obes Metab.
Huang CJ, Wang WT, Sung SH, Chen CH, Lip GY, Cheng HM, Chiang CE
doi: 10.1111/dom.13342.
Type 2 DiabetesGlycemic Control
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Lancet Diabetes Endocrinol.
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
doi: 10.1016/S2213-8587(17)
COMMENTED
Type 2 Diabetes
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis
Diabetes Obes Metab.
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V
doi: 10.1111/dom.
COMMENTED
Type 2 Diabetes
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
doi: 10.1016/S0140-6736
Diabetes - GeneralGlycemic Control
Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis
Diabetes Care.
Mannucci E, Mosenzon O, Avogaro A
doi: 10.2337/dcS15-3024.